Intelligence · Clinical Development
Pipeline search results
Programs matching “air” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 160 pipeline programs matching "air" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
67652000PCR3002
Janssen-Cilag International N.V.
Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
1 trial -
91774
Bayer HealthCare AG
Metrorrhagia
1 trial -
91781
Bayer HealthCare AG
Primary Dysmenorrhea
1 trial -
APHP220674
Pari Pharma GmbH
respiratory distress due to upper airway obstruction in child
1 trial -
APHP230836
Pari Pharma GmbH
Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.
1 trial -
Actovegin
Takeda
Post-Stroke Cognitive Impairment (PSCI)
1 trial -
CA209-8HW
Bristol-Myers Squibb Australia Pty Ltd
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)
1 trial -
D6402C00012
AstraZeneca
Heart Failure and Impaired Kidney Function
1 trial -
D6402C00012
AstraZeneca AB
Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death
1 trial -
DESTINYEndometrial01
AstraZeneca AB
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
1 trial -
EV/DNG (Qlaira, BAY86-5027)
Bayer HealthCare AG
Oral Contraceptive
1 trial -
Idursulfase (idursulfase-IT [HGT-2310])
Takeda
Hunter Syndrome and Cognitive Impairment
1 trial -
KamadaAATInhaled008
Kamada BioPharma Limited at Fieldfisher LLP
Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.
1 trial -
Lecanemab
Eisai Co.,
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.
1 trial -
Metalyse 5 000 units (25 mg) powder for solution for injection
Pari Pharma GmbH
Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.
1 trial -
NN6535-4725
NovoThirteen
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
1 trial -
NN6535-4730
NovoThirteen
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
1 trial -
NN6535-7519
NovoThirteen
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
1 trial -
NN9490-8025
NovoThirteen
Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure
1 trial -
NN9490-8293
NovoThirteen
Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)
1 trial -
Omalizumab (Xolair)
BRIGHT MINDS BIOSCIENCES INC.
Chronic Urticaria
1 trial -
Pioglitazone
Takeda
Mild Cognitive Impairment Due to Alzheimer's Disease
2 trials -
Pioglitazone
Takeda
Impaired Glucose Tolerance
1 trial -
RIPH_2019_01
Tour Hekla
Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.